Safety, Tolerability, and Efficacy Study of LFX453 in Actinic Keratosis Patients

NCT02404389 PHASE2 COMPLETED Results posted

This is a randomized, vehicle controlled, active comparator, parallel group, study with a total duration of 24 weeks including screening and follow-up. Study drug is applied topically for 2 cycles of 4 week treatment, separated by 4 weeks off-treatment. Assessors of study endpoints are blinded to treatment allocation.

Details

Lead sponsor	Novartis Pharmaceuticals
Phase	PHASE2
Status	COMPLETED
Enrolment	82
Start date	Thu Mar 05 2015 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Wed Jan 27 2016 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

• Actinic Keratosis

Interventions

• Investigational Treatment
• Active comparator

Countries

Denmark, Austria, United Kingdom, Germany, Iceland